Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers
Abstract Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies. Individual data on 2954 adult patie...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-08-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.208 |
| _version_ | 1797740012019646464 |
|---|---|
| author | Emma Hernlund Josefine Redig Björn Paulsson Åsa Rangert Derolf Martin Höglund Simona Vertuani Gunnar Juliusson |
| author_facet | Emma Hernlund Josefine Redig Björn Paulsson Åsa Rangert Derolf Martin Höglund Simona Vertuani Gunnar Juliusson |
| author_sort | Emma Hernlund |
| collection | DOAJ |
| description | Abstract Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies. Individual data on 2954 adult patients diagnosed from 2007 to 2015 from five Swedish national population‐based registers were used, enabling analyses from diagnosis to either death or 5‐year follow‐up for survival, inpatient and outpatient costs, costs of prescribed drugs, sick leave, and early retirement. Costs per patient were stratified by age group, treatment options, and FLT3‐ITD status. The expected 5‐year costs per patient differed substantially between age groups. Patients aged 18–59 years had an expected mean cost per patient of €170,748, while age groups 60–69 years, 70–79 years, and >80 years incurred an expected mean cost of €92,252, €48,344, and €24,118, respectively, over 5 years. Patients <60 years undergoing stem cell transplantation had the highest costs (€228,525 over 5 years). About 60% of costs for these patients were from hospitalizations and 20% from sick leave and early retirement; cost per day was highest from the first admission to complete remission. This study provides a baseline for socioeconomic evaluations of novel therapies in AML in Sweden. |
| first_indexed | 2024-03-12T14:05:30Z |
| format | Article |
| id | doaj.art-2521e01d50814855bd52aa8725211ff4 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:05:30Z |
| publishDate | 2021-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-2521e01d50814855bd52aa8725211ff42023-08-21T14:10:34ZengWileyeJHaem2688-61462021-08-012338539310.1002/jha2.208Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registersEmma Hernlund0Josefine Redig1Björn Paulsson2Åsa Rangert Derolf3Martin Höglund4Simona Vertuani5Gunnar Juliusson6ICON plc Stockholm SwedenICON plc Stockholm SwedenNovartis Oncology Nordics Stockholm SwedenSwedish Acute Myeloid Leukemia Registry GroupSwedish Acute Myeloid Leukemia Registry GroupNovartis Oncology Nordics Stockholm SwedenSwedish Acute Myeloid Leukemia Registry GroupAbstract Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies. Individual data on 2954 adult patients diagnosed from 2007 to 2015 from five Swedish national population‐based registers were used, enabling analyses from diagnosis to either death or 5‐year follow‐up for survival, inpatient and outpatient costs, costs of prescribed drugs, sick leave, and early retirement. Costs per patient were stratified by age group, treatment options, and FLT3‐ITD status. The expected 5‐year costs per patient differed substantially between age groups. Patients aged 18–59 years had an expected mean cost per patient of €170,748, while age groups 60–69 years, 70–79 years, and >80 years incurred an expected mean cost of €92,252, €48,344, and €24,118, respectively, over 5 years. Patients <60 years undergoing stem cell transplantation had the highest costs (€228,525 over 5 years). About 60% of costs for these patients were from hospitalizations and 20% from sick leave and early retirement; cost per day was highest from the first admission to complete remission. This study provides a baseline for socioeconomic evaluations of novel therapies in AML in Sweden.https://doi.org/10.1002/jha2.208acute leukemiacostnational registerstreatment |
| spellingShingle | Emma Hernlund Josefine Redig Björn Paulsson Åsa Rangert Derolf Martin Höglund Simona Vertuani Gunnar Juliusson Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers eJHaem acute leukemia cost national registers treatment |
| title | Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers |
| title_full | Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers |
| title_fullStr | Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers |
| title_full_unstemmed | Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers |
| title_short | Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers |
| title_sort | socioeconomic cost of aml in sweden a population based study using multiple nation wide registers |
| topic | acute leukemia cost national registers treatment |
| url | https://doi.org/10.1002/jha2.208 |
| work_keys_str_mv | AT emmahernlund socioeconomiccostofamlinswedenapopulationbasedstudyusingmultiplenationwideregisters AT josefineredig socioeconomiccostofamlinswedenapopulationbasedstudyusingmultiplenationwideregisters AT bjornpaulsson socioeconomiccostofamlinswedenapopulationbasedstudyusingmultiplenationwideregisters AT asarangertderolf socioeconomiccostofamlinswedenapopulationbasedstudyusingmultiplenationwideregisters AT martinhoglund socioeconomiccostofamlinswedenapopulationbasedstudyusingmultiplenationwideregisters AT simonavertuani socioeconomiccostofamlinswedenapopulationbasedstudyusingmultiplenationwideregisters AT gunnarjuliusson socioeconomiccostofamlinswedenapopulationbasedstudyusingmultiplenationwideregisters |